Why the study?
What are the risk factors for the prolongation of APTT associated with dabigatran therapy in patients with non-valvular atrial fibrillation?
What are the risk factors for the prolongation of APTT associated with dabigatran therapy in patients with non-valvular atrial fibrillation?
Decreased creatinine clearance and concomitant use of P-glycoprotein inhibitors are significant risk factors for excessive APTT prolongation during dabigatran therapy in NVAF patients.
No takes yet. Share an insight, caveat, or question.
May warrant APTT monitoring in low-Ccr or P-gp inhibitor patients; leaves open outcome validation.
Tanaka et al. (2015) studied this question.